Preferred Label : B16alphaGal Melanoma Vaccine;
NCIt definition : A whole cell melanoma cancer vaccine with potential immunostimulating and antineoplastic
activities. B16alphaGal melanoma vaccine contains three types of human melanoma cell
lines that are genetically engineered to express the alpha(1,3)-galactosyl (alphaGal)
epitope on cell surfaces. The agent stimulates a hyperacute rejection of whole melanoma
cancer cells expressing alphaGal epitopes, initiated by opsonization by anti-alphaGal
antibodies and followed by antibody-dependent cell-mediated cytotoxicity (ADCC) and
cell lysis. This results in the stimulation of a broader cytotoxic T-lymphocyte response
(CTL) directed against tumor antigens on melanoma cells that do not express alphaGal.
AlphaGal is not normally expressed in humans because alpha(1,3)-galactosyltransferase
(Alpha-GT), the enzyme that catalyzes the synthesis of alphaGal epitopes on glycoproteins
and glycolipids, is not naturally present in humans and other primates.;
Drug name : Hyperacute Melanoma;
NCI Metathesaurus CUI : CL388386;
Origin ID : C80046;
UMLS CUI : C2698295;
Semantic type(s)
- concept_is_in_subset
